Marschitz I - Search Results

1

Quality of life measurement in oncology--a matter of the assessment instrument?

Holzner B, Kemmler G, Sperner-Unterweger B, Kopp M, Dünser M, Margreiter R, Marschitz I, Nachbaur D, Fleischhacker WW, Greil R. Holzner B, et al. Among authors: marschitz i. Eur J Cancer. 2001 Dec;37(18):2349-56. doi: 10.1016/s0959-8049(01)00307-0. Eur J Cancer. 2001. PMID: 11720827

2

Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques.

Marschitz I, Tinhofer I, Hittmair A, Egle A, Kos M, Greil R. Marschitz I, et al. Am J Clin Pathol. 2000 Feb;113(2):219-29. doi: 10.1309/491W-L1TN-UFQX-T61B. Am J Clin Pathol. 2000. PMID: 10664624

3

Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.

Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, Greil R. Tinhofer I, et al. Among authors: marschitz i. Blood. 1998 Jun 1;91(11):4273-81. Blood. 1998. PMID: 9596676 Free article.

4

Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.

Tinhofer I, Marschitz I, Henn T, Egle A, Greil R. Tinhofer I, et al. Among authors: marschitz i. Blood. 2000 Jan 15;95(2):610-8. Blood. 2000. PMID: 10627470 Free article.

5

Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.

Egle A, Villunger A, Marschitz I, Kos M, Hittmair A, Lukas P, Grünewald K, Greil R. Egle A, et al. Among authors: marschitz i. Br J Haematol. 1997 May;97(2):418-28. doi: 10.1046/j.1365-2141.1997.382680.x. Br J Haematol. 1997. PMID: 9163609 Free article.

6

IL-10 serum levels in B-cell chronic lymphocytic leukaemia.

Egle A, Marschitz I, Posch B, Herold M, Greil R. Egle A, et al. Among authors: marschitz i. Br J Haematol. 1996 Jul;94(1):211-2. Br J Haematol. 1996. PMID: 8757538 No abstract available.

7

Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.

Villunger A, Egle A, Marschitz I, Kos M, Böck G, Ludwig H, Geley S, Kofler R, Greil R. Villunger A, et al. Among authors: marschitz i. Blood. 1997 Jul 1;90(1):12-20. Blood. 1997. PMID: 9207432 Free article.

8

Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia.

Anether G, Marschitz I, Tinhofer I, Greil R. Anether G, et al. Among authors: marschitz i. Blood. 2002 Jan 15;99(2):722-3. doi: 10.1182/blood.v99.2.722. Blood. 2002. PMID: 11799965 Free article. No abstract available.

9

The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia.

Schwarzmeier JD, Shehata M, Hilgarth M, Marschitz I, Louda N, Hubmann R, Greil R. Schwarzmeier JD, et al. Among authors: marschitz i. Leuk Lymphoma. 2002 Mar;43(3):549-54. doi: 10.1080/10428190210323. Leuk Lymphoma. 2002. PMID: 12002758

10

Gastric cancer cell lines lack Fas ligand (FasL) expression but kill T cells via a FasL independent pathway.

Tinhofer I, Wykypiel H, Marschitz I, Henn T, Greil R. Tinhofer I, et al. Among authors: marschitz i. Gut. 2000 May;46(5):738-40. doi: 10.1136/gut.46.5.738. Gut. 2000. PMID: 10836854 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters